BOSTON, Feb. 25, 2026 (GLOBE NEWSWIRE) -- Elicio Therapeutics, Inc. (Nasdaq: ELTX, “Elicio” or the “Company”), a clinical-stage biotechnology company developing a pipeline of novel immunotherapies for the treatment of cancer, today announced that Robert Connelly, Chief Executive Officer, and Pete DeMuth, PhD, Chief Scientific Officer, will participate in the upcoming TD Cowen 46th Annual Health Care Conference, taking place March 2-4, 2026, in Boston, MA. TD Cowen 46th Annual Health Care ConferenceFormat: ...

SAN DIEGO, Feb. 25, 2026 (GLOBE NEWSWIRE) -- Artiva Biotherapeutics, Inc. (Nasdaq: ARTV), a clinical-stage biotechnology company whose mission is to develop effective, safe and accessible cell therapies for patients with devastating autoimmune diseases and cancers, today announced that Artiva management will participate in a fireside chat at the TD Cowen 46th Annual Health Care Conference on Wednesday, March 4, 2026, at 1:10 p.m. EST, in Boston, MA. Members of the Artiva management team will also be availab ...

Important Information This presentation of Recursion Pharmaceuticals, Inc. ("Recursion," "we," "us," or "our") and any accompanying discussion contain statements that are not historical facts may be considered forward-looking statements under federal securities laws and may be identified by words such as "anticipates," "believes," "estimates," "expects," "intends," "plans," "potential," "predicts," "projects," "seeks," "should," "will," or words of similar meaning and include, but are not limited to, statem ...

Partnership will leverage Vivtex’s proprietary technologies built to identify optimal oral formulations for peptide and protein therapeutics with improved bioavailabilityNovo Nordisk will lead global development and commercialization, and Vivtex is eligible to receive up to 2.1 billion US dollars, as well as royalties on net sales of future productsPartnership expands Vivtex’s platform to metabolic diseases and supports Novo Nordisk’s mission to deliver scalable and innovative medicines to people with obesi ...

AUSTIN, TX and DURHAM, NC, Feb. 25, 2026 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (NASDAQ: STTK), a clinical-stage biotechnology company pioneering the development of potentially first-in-class monoclonal and bispecific DR3-blocking antibodies for the treatment of patients with inflammatory and immune-mediated diseases, today announced that company management will present at and participate in the following upcoming investor conferences: Conference Details TD Cowen 46th Annual Health Care Conferen ...

With a market cap of $206.4 billion, Amgen Inc. (AMGN) is a global biotechnology company that discovers, develops, manufactures, and delivers innovative human therapeutics for serious diseases worldwide. Headquartered in Thousand Oaks, California, Amgen serves healthcare providers globally and collaborates with major biopharmaceutical partners to expand and advance its pipeline. Companies valued at $200 billion or more are generally considered “mega-cap” stocks, and Amgen fits this criterion perfectly. I ...

WALTHAM, Mass., Feb. 25, 2026 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage company focused on delivering functional improvement for people living with genetically driven neuromuscular diseases, today announced that management is scheduled to participate in the following upcoming investor conferences: TD Cowen 46th Annual Health Care Conference, fireside chat on Wednesday, March 4, 2026 at 11:50 a.m. ET in Boston, MA2026 Jefferies Biotech on the Beach Summit, hosting meetings o ...

Toronto, Ontario--(Newsfile Corp. - February 25, 2026) - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a late-stage life sciences company focused on advancing the development of anti-inflammatory and anti-fibrotic therapies for heart disease, is pleased to announce that it will participate at the upcoming TD Cowen 46th Annual Health Care Conference in Boston, MA. Members of management will present on March 4, 2026, at 10:30 a.m. EST.A live webcast of the Company's prese ...

Core Insights - Ironwood Pharmaceuticals reported its fourth quarter and full year 2025 results, highlighting significant developments in its product LINZESS and the advancement of apraglutide [1][2]. Financial Performance - Total revenue for Q4 2025 was $47.7 million, down from $90.5 million in Q4 2024. For the full year 2025, total revenue was $296.2 million, compared to $351.4 million in 2024 [3][11]. - GAAP net loss for Q4 2025 was $2.3 million, or $(0.01) per share, compared to a net income of $2.3 million, or $0.01 per share, in Q4 2024. For the full year 2025, GAAP net income was $24.0 million, or $0.15 per share, compared to $0.9 million, or $0.01 per share, in 2024 [3][40]. - Adjusted EBITDA for Q4 2025 was $10.9 million, down from $37.3 million in Q4 2024. For the full year 2025, adjusted EBITDA was $138.1 million, compared to $129.4 million in 2024 [3][12]. Product Performance - LINZESS achieved 11% year-over-year demand growth in 2025, treating over 5.7 million unique patients since its launch. However, U.S. net sales for LINZESS were $163.2 million in Q4 2025, a 27% decrease from $223.0 million in Q4 2024, and $864.5 million for the full year 2025, a 6% decrease from $916.3 million in 2024 [2][8][9]. - Total LINZESS prescription demand in Q4 2025 was 63 million capsules, a 13% increase compared to Q4 2024, and 234 million capsules for the full year 2025, an 11% increase compared to 2024 [8][9]. Strategic Initiatives - The company plans to focus on maximizing LINZESS, advancing apraglutide, and delivering sustained profits and cash flows in 2026. The financial guidance for 2026 includes expected U.S. LINZESS net sales of $1.125 - $1.175 billion and adjusted EBITDA exceeding $300 million [2][13]. - Apraglutide is being developed for short bowel syndrome patients dependent on parenteral support, with a Phase 3 clinical trial (STARS-2) expected to initiate in Q2 2026 [8][10]. Corporate Developments - In December 2025, Ironwood entered into a settlement agreement with Ferring International Center S.A., agreeing to pay $12.5 million, with $7.5 million paid in December 2025 and the remaining $5.0 million due by December 31, 2026 [10].

REGENXBIO to Host Conference Call on March 5 to Discuss Fourth Quarter and Full Year 2025 Financial Results and Operational Highlights [Accessibility Statement] Skip NavigationROCKVILLE, Md., Feb. 25, 2026 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced that it will host a conference call on Thursday, March 5, at 8:00 a.m. ET to discuss its financial results for the fourth quarter and full year ended December 31, 2025, and operational highlights.Listeners can register for the webcast via this ...